Episurf Medical provides market share target at today's Capital Markets Day

Episurf Medical AB (Nasdaq: EPIS B), hosts its Digital Capital Markets Day today at 13.00 CEST - 16.00 CEST. The purpose of the Capital Markets Day is to increase the understanding of Episurf Medical’s business, technology, clinical results, and future opportunities. Episurf Medical is also providing market share targets for the first product line, the Episealer® knee technology, in the initially prioritized markets. The company also comments on the commercial activities in the third quarter.

Through the EPIC-Knee study, Episurf Medical is executing on its strategy to launch its Episealer® knee technology in the US market. Episurf has early-stage commercial activities in certain European countries, and after completion of the EPIC-Knee study and FDA approval, the large US market becomes available.

The long-term target is to achieve a 30% market share in the initially prioritized markets (US, Germany, UK, Nordics, Switzerland, Benelux and certain other EU markets). Within three years from market launch in the US market, Episurf expects to reach a 15% market share in all prioritized markets. Episurf Medical estimates the total addressable market to be worth more than USD 1 billion annually. There is a strong underlying growth in the market due to demographic factors and technological advancements. During the period up to FDA approval, the company targets substantial revenue growth on an annual basis. During this period, the company also expects to meet several important clinical and operational milestones, as Episurf expects to get more and more traction in the current markets, due to the presentation of clinical data, both long- and short-term, that continuously have been generated.

During the Capital Markets Day, CEO Pål Ryfors, members of the management team and key customers and co-operation partners of Episurf will present various aspects of the business. Full agenda is available at Episurf’s website www.episurf.com.

“We want to assure our shareholders that we maintain a razor-sharp focus on achieving profitability with our Episealer® knee implant technology in our initial markets. At the same time, investors can look forward to increases in our total addressable market as opportunities crystallize in additional geographies or in new areas such as the ankle market. Today we seek to communicate that our highest priority is growing our existing business, while still keeping an eye on the future,” says Pål Ryfors, CEO Episurf Medical.

Episurf Medical announces that the third quarter’s commercial activity has progressed well despite the decreased level of elective surgeries in Europe due to Covid-19. The third quarter of 2020 will be the best quarter ever, as measured by the number of Episealer® implants ordered.

For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel: +46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12.30 CEST on 15 September 2020.